Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Financials, Basic Materials and Industrials sectors led shares higher. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Utilities, Basic Materials and Telecoms sectors led shares higher. At the close in NYSE, the Dow...
Noteworthy events during the week of November 25 - December 1 for healthcare investors. MONDAY (11/26): FDA action date for Loxo Oncology's (NASDAQ:LOXO) larotrectinib in NTRK...
Let’s talk about growth stocks. These are stocks that have shown strong and sustained share price appreciation, sometimes ranging into triple-digit gains over the course of a...
Verastem, Inc. (NASDAQ:VSTM) has been struggling lately, but the selling pressure may be coming to an end soon. That is because VSTM recently saw a Hammer Chart Pattern which can...
As of late, it has definitely been a great time to be an investor in Verastem, Inc. ( (NASDAQ:VSTM) ). The stock has moved higher by 38.5% in the past month, while it is also above...
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen’s KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Neutral | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 82.31 | 84.07 | 81.07 | -0.16 | -0.19% | 22.86M | NYSE | |||
| 1.15 | 1.20 | 0.96 | -0.090 | -7.28% | 150.01K | NASDAQ | |||
| 10.16 | 10.16 | 10.16 | 0.000 | 0.00% | 10.90K | NASDAQ | |||
| 168.97 | 169.49 | 166.96 | +1.15 | +0.69% | 5.77M | NASDAQ | |||
| 92.65 | 93.89 | 89.52 | +1.49 | +1.63% | 109.22M | NASDAQ | |||
| 120.38 | 127.46 | 119.18 | -4.03 | -3.24% | 3.52M | NYSE | |||
| 18.28 | 18.39 | 16.80 | +1.04 | +6.03% | 1.55M | NASDAQ | |||
| 0.64 | 0.82 | 0.63 | -0.14 | -18.26% | 815.52K | NASDAQ | |||
| 17.07 | 17.14 | 16.98 | +0.01 | +0.06% | 163.50K | OTC Markets | |||
| 14.61 | 14.69 | 14.46 | +0.10 | +0.69% | 100.82K | OTC Markets | |||
| 531.63 | 537.45 | 523.90 | +7.43 | +1.42% | 1.76M | NASDAQ | |||
| 2,147.22 | 2,167.36 | 2,038.07 | +97.16 | +4.74% | 355.02K | NASDAQ | |||
| 9.27 | 9.44 | 8.84 | +0.27 | +3.00% | 6.80M | NASDAQ | |||
| 108.20 | 108.89 | 103.46 | +0.91 | +0.85% | 7.15M | NYSE | |||
| 10.25 | 10.25 | 10.24 | 0.00 | 0.00% | 0.00 | NASDAQ |